| pubmed-article:15383007 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15383007 | lifeskim:mentions | umls-concept:C2349001 | lld:lifeskim |
| pubmed-article:15383007 | lifeskim:mentions | umls-concept:C0681850 | lld:lifeskim |
| pubmed-article:15383007 | lifeskim:mentions | umls-concept:C1706203 | lld:lifeskim |
| pubmed-article:15383007 | lifeskim:mentions | umls-concept:C2697811 | lld:lifeskim |
| pubmed-article:15383007 | lifeskim:mentions | umls-concept:C0007412 | lld:lifeskim |
| pubmed-article:15383007 | lifeskim:mentions | umls-concept:C0020615 | lld:lifeskim |
| pubmed-article:15383007 | lifeskim:mentions | umls-concept:C0287041 | lld:lifeskim |
| pubmed-article:15383007 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:15383007 | lifeskim:mentions | umls-concept:C0205100 | lld:lifeskim |
| pubmed-article:15383007 | lifeskim:mentions | umls-concept:C1550501 | lld:lifeskim |
| pubmed-article:15383007 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:15383007 | pubmed:dateCreated | 2005-1-18 | lld:pubmed |
| pubmed-article:15383007 | pubmed:abstractText | ANG II (angiotensin II) facilitates catecholamine release from the adrenal medulla and neuronal NE (noradrenaline) release. Since animal experiments point to specific sympatho-inhibitory properties of the AT1 (ANG II type 1)-receptor blocker EPRO (eprosartan), the primary aim of this study was to clarify if EPRO inhibits sympathetic reactivity in humans as determined by the effect of EPRO on insulin-induced catecholamine release. Sixteen healthy male volunteers were randomized in a double-blind cross-over study to receive a single dose of EPRO (600 mg) compared with placebo, followed by insulin-induced hypoglycaemia [0.15 IU (international unit)/kg of body weight; intravenous bolus] on two study days 1 week apart. From baseline to the end of hypoglycaemia (170 min), the sympatho-adrenal reactivity was mapped by invasive continuous blood pressure monitoring and repeated measurements of FBF (forearm blood flow), arterial and venous concentrations of glucose, catecholamines [EPI (adrenaline) and NE (noradrenaline)], renin, ANG II and aldosterone. EPRO induced an 8-10-fold increase in plasma renin and ANG II concentrations compared with placebo. Plasma glucose decreased equally during placebo and EPRO from baseline 5.9 mmol/l to 1.9 mmol/l and 2.1 mmol/l respectively, inducing a 17-fold increase in arterial EPI concentration at peak. The AUC (area under the curve) during hypoglycaemia for arterial EPI concentrations was 314+/-48 nmol.min.l-1 in placebo compared with 254+/-26 nmol.min.l-1 following EPRO treatment (P=0.14). EPRO attenuated the corresponding AUC for the EPI-induced pulse pressure response (4670+/-219 mmHg.min in EPRO compared with 5004+/-266 mmHg.min in placebo; P=0.02). Moreover, EPRO caused a less pronounced increase in FBF compared with placebo (402+/-30 compared with 479+/-46 ml.100 g-1 of body weight; P=0.04). Musculocutaneous NE release was not affected by EPRO and the AUC for NE release was 51.69+/-15.5 pmol.min-1.100 g-1 of body weight in placebo compared with 39.35+/-18.2 pmol.min-1.100 g-1 of body weight after EPRO treatment (P=0.57). In conclusion, EPRO did not significantly inhibit sympathetic reactivity compared with placebo; however, it blunted the haemodynamic responses elicited by the sympatho-adrenal stimulation which only tended to be attenuated by this drug. | lld:pubmed |
| pubmed-article:15383007 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15383007 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15383007 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15383007 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15383007 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15383007 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15383007 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15383007 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15383007 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15383007 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15383007 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15383007 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15383007 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15383007 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:15383007 | pubmed:issn | 0143-5221 | lld:pubmed |
| pubmed-article:15383007 | pubmed:author | pubmed-author:IbsenHansH | lld:pubmed |
| pubmed-article:15383007 | pubmed:author | pubmed-author:ChristensenMa... | lld:pubmed |
| pubmed-article:15383007 | pubmed:author | pubmed-author:WorckRenéR | lld:pubmed |
| pubmed-article:15383007 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15383007 | pubmed:volume | 108 | lld:pubmed |
| pubmed-article:15383007 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15383007 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15383007 | pubmed:pagination | 113-9 | lld:pubmed |
| pubmed-article:15383007 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:15383007 | pubmed:meshHeading | pubmed-meshheading:15383007... | lld:pubmed |
| pubmed-article:15383007 | pubmed:meshHeading | pubmed-meshheading:15383007... | lld:pubmed |
| pubmed-article:15383007 | pubmed:meshHeading | pubmed-meshheading:15383007... | lld:pubmed |
| pubmed-article:15383007 | pubmed:meshHeading | pubmed-meshheading:15383007... | lld:pubmed |
| pubmed-article:15383007 | pubmed:meshHeading | pubmed-meshheading:15383007... | lld:pubmed |
| pubmed-article:15383007 | pubmed:meshHeading | pubmed-meshheading:15383007... | lld:pubmed |
| pubmed-article:15383007 | pubmed:meshHeading | pubmed-meshheading:15383007... | lld:pubmed |
| pubmed-article:15383007 | pubmed:meshHeading | pubmed-meshheading:15383007... | lld:pubmed |
| pubmed-article:15383007 | pubmed:meshHeading | pubmed-meshheading:15383007... | lld:pubmed |
| pubmed-article:15383007 | pubmed:meshHeading | pubmed-meshheading:15383007... | lld:pubmed |
| pubmed-article:15383007 | pubmed:meshHeading | pubmed-meshheading:15383007... | lld:pubmed |
| pubmed-article:15383007 | pubmed:meshHeading | pubmed-meshheading:15383007... | lld:pubmed |
| pubmed-article:15383007 | pubmed:meshHeading | pubmed-meshheading:15383007... | lld:pubmed |
| pubmed-article:15383007 | pubmed:meshHeading | pubmed-meshheading:15383007... | lld:pubmed |
| pubmed-article:15383007 | pubmed:meshHeading | pubmed-meshheading:15383007... | lld:pubmed |
| pubmed-article:15383007 | pubmed:meshHeading | pubmed-meshheading:15383007... | lld:pubmed |
| pubmed-article:15383007 | pubmed:meshHeading | pubmed-meshheading:15383007... | lld:pubmed |
| pubmed-article:15383007 | pubmed:meshHeading | pubmed-meshheading:15383007... | lld:pubmed |
| pubmed-article:15383007 | pubmed:meshHeading | pubmed-meshheading:15383007... | lld:pubmed |
| pubmed-article:15383007 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15383007 | pubmed:articleTitle | Effect of eprosartan on catecholamines and peripheral haemodynamics in subjects with insulin-induced hypoglycaemia. | lld:pubmed |
| pubmed-article:15383007 | pubmed:affiliation | Department of Clinical Physiology and Nuclear Medicine, Glostrup University Hospital, DK-2600 Glostrup, Denmark. macn@glostruphosp.kbhamt.dk | lld:pubmed |
| pubmed-article:15383007 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15383007 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:15383007 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:15383007 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15383007 | lld:pubmed |
